Autoimmune Diseases

Cullinan Inks $700M Deal for BCMA Bispecific to Expand Autoimmune T-Cell Engager Portfolio

3 days ago talkbio0Tagged Autoimmune Diseases, biotech partnerships, bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine, bispecific, CD19xCD3, Clinical Development, CLN-978, Cullinan, Genrix Bio, Multiple Myeloma, T-Cell engager, velinotamig

Cullinan Therapeutics; Genrix Bio; BCMA bispecific; velinotamig; T-cell engager; autoimmune disease; CD19xCD3; CLN-978; multiple myeloma; clinical development; biotech partnerships

Kymera Soars on Early Protein Degrader Data

5 days ago talkbio0Tagged Autoimmune Diseases, Clinical Trials, KT-621, Kymera, Phase 1 (qualifier value), Protein Degradation, Metabolic, STAT6 degrader

Kymera Therapeutics; KT-621; STAT6 degrader; protein degradation; Phase 1 clinical trial; autoimmune disease

GlycoEra Raises $130M to Advance Protein Degraders Toward Clinic

2 weeks ago talkbio0Tagged Autoantibodies, Autoimmune Diseases, Clinical Trials, Funding, GE8820, GlycoEra, Holdings, Immunoglobulin IgG4, Precision Immunology, protein degraders

GlycoEra; protein degraders; $130 million funding; autoimmune diseases; GE8820; IgG4 autoantibodies; Novo Holdings; clinical trial; precision immunology

Kyverna Therapeutics Cuts 16% of Staff in Q1 2025 Amid Pipeline Focus

3 weeks ago talkbio0Tagged Autoimmune Diseases, CAR-T, KYV-101, Kyverna, layoffs, pipeline development, Staff

Kyverna Therapeutics; layoffs; biotech; staff reduction; Q1 2025; CAR-T; autoimmune diseases; pipeline development; KYV-101

FDA Approves Johnson & Johnson’s Imaavy: A New Treatment Option for Generalized Myasthenia Gravis

1 month ago talkbio0Tagged Approved, Autoimmune Diseases, Blocker, FCGRT gene, FcRn, Imaavy, immunoglobulin G, Myasthenia Gravis, Generalized, nipocalimab-aahu, United States Food and Drug Administration

Imaavy, nipocalimab-aahu, FcRn blocker, generalized myasthenia gravis (gMG), FDA approval, Johnson & Johnson, autoimmune disease, IgG reduction

Octagon Therapeutics Ceases Operations Due to R&D Challenges and Unresolved Biology Questions

1 month ago talkbio0Tagged Autoimmune Diseases, B cell immunomodulator program, biology (field), Flatulence, Nordisk alliance, OCT50, Programs - Publication Format

Autoimmune disease biotech, B cell immunomodulator program, OCT50 program, Novo Nordisk alliance, Winding down operations, Unresolved biology challenges

Versant’s Granite Bio unveils with $100M for new autoimmune disease antibodies

1 month ago talkbio0Tagged Autoimmune Diseases, granite, GRT-001, interleukin-3, Versant

Autoimmune Diseases, granite, GRT-001, Versant, interleukin-3

Roche’s Genentech builds autoimmune Repertoire with deal worth up to $765M

2 months ago talkbio0Tagged Autoimmune Diseases, genentech, Immune Medicines, Partnership, Repertoire

Repertoire, genentech, Autoimmune Diseases, Immune Medicines, Partnership

Descartes-08: Sustained Efficacy in Myasthenia Gravis as Cartesian Prepares for Phase III Trial

2 months ago talkbio0Tagged Autoimmune Diseases, Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes, CAR-T, Cartesian, Clinical Trials, gMG, mRNA-based, Myasthenia Gravis, Phase III AURORA trial

Descartes-08 , Myasthenia Gravis (gMG) , CAR-T therapy , Cartesian Therapeutics , mRNA-based treatment , Phase III AURORA trial , Autoimmune diseases , Clinical trial results

Exclusive: Merida Biosciences gets $121M to treat autoimmune and allergy diseases at their roots

2 months ago talkbio0Tagged Autoimmune, Autoimmune Diseases, Precision - temporal

Autoimmune, Autoimmune Diseases, Precision – temporal